Key Dates

Related Announcements

PAR-22-173 Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional)

Issued by

National Cancer Institute (NCI)

Purpose

The purpose of this notice is to correct the Non-Responsive Application criteria in Funding Opportunity Announcement (FOA) PAR-22-173, “Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional)".

The following section of PAR-22-173 has been modified:

Section I. Funding Opportunity Description

Non-Responsive Applications

Currently Reads

Applications with the following attributes will be deemed non-responsive and will not be reviewed:

• Applications that are first-in-human studies.
• Applications that only propose to write a protocol or manual, develop infrastructure, or implement an already fully designed trial.
• Applications that include purely mechanistic work or contain animal studies.
• Applications that lack a milestone plan, an organization plan and/or a stakeholder engagement plan.

Modified to Read (changes shown in bold italics):

Applications with the following attributes will be deemed non-responsive and will not be reviewed:

• Applications that are first-in-human studies.
• Applications that only propose to write a protocol or manual, develop infrastructure, or implement an already fully designed trial.
• Applications that include purely mechanistic work or contain animal studies.
• Applications that lack a milestone plan, stakeholder engagement plan, and/ or future clinical trial description.

All other aspects of the FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Brandy Heckman-Stoddard, Ph.D., M.P.H.
National Cancer Institute (NCI)
Telephone: 240-276-7048
Email: [email protected]